Two inspections by the US Food and Drug Administration, an internal company investigation, and an inspection by a third party found instances of misconduct and other violations at a Cetero Research facility in Houston, reports Reuters. "The pattern of misconduct was serious enough to raise concerns about the integrity of the data Cetero generated during the five-year time frame," FDA said.